Back to top

BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

Citi notes that BioAge Labs (BIOA) shares are down greater than 60% following the news that Novo Nordisk’s (NVO) ZEUS trial for ziltivekimab failed...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

NOV Inc. (NOV)

Novo Nordisk A/S (NVO)